Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Sclerosis, Scleroderma Clear all

Conditions: ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions: FT839; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Rheumatologic Disease
Interventions: BH4, Vasculopathy assessment, Placebo; Drug · Diagnostic Test
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 95 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease With Systemic Sclerosis
Interventions: FAPI tracer; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Scleroderma
Interventions: Mindfulness Based Stress Reduction (MBSR), Control; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Eosinophilic Fasciitis
Interventions: Not listed
Lead sponsor: Meyer Children's Hospital IRCCS; Other
Eligibility: Up to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Syracuse, New York

Conditions: Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions: UVB Irradiation; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 10 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Sclerosis
Interventions: treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Systemic Scleroderma
Interventions: Spatial-frequency domain imaging (SFDI); Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Scleroderma, Severe Systemic Sclerosis
Interventions: fludarabine phosphate, Mycophenolic Acid, tacrolimus, total-body irradiation, bone marrow transplantation, reduced intensity allogeneic hematopoietic stem cell transplantation, quality-of-life assessment, laboratory biomarker analysis, flow cytometry, biopsy; Drug · Radiation · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Systemic Sclerosis (SSc), Scleroderma
Interventions: Tibulizumab, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Nonmyeloablative allogeneic stem cell transplant; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Scleroderma
Interventions: BMS-986020, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 19
States / cities: Scottsdale, Arizona • Los Angeles, California • Stanford, California + 13 more

Conditions: Systemic Sclerosis
Interventions: SAR100842, Placebo (for SAR100842); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more

Conditions: Scleroderma
Interventions: RENEW; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Scleroderma
Interventions: Botulinum toxin(Botox); Biological
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Achalasia, Nutcracker Esophagus, Scleroderma, Esophageal Spasm, Fecal Incontinence
Interventions: Air filled balloon catheter, Solid state catheter; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Systemic Sclerosis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions: Allogeneic NK Cells; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Scleroderma
Interventions: Optical Elastography, Visual Assessment; Device · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Interventions: Tulisokibart, Companion diagnostic ( CDx), Placebo; Drug · Diagnostic Test
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions: HZN-825; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more

Search by objective public record fields.

FT839 in Autoimmune Diseases

Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment

FAPI PET in Systemic Sclerosis Interstitial Lung Disease

Study of Silicone-Associated Connective Tissue Diseases

Mindfulness Based Stress Reduction in Rheumatic Diseases

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

Open-Label Study of Oral Treprostinil in Digital Ulcers

Longitudinal Spatial Frequency Domain Imaging Study

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue

The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma

Comparison of Esophageal and Anorectal Manometry Catheters

Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

Optical Elastography of Systemic Sclerosis Skin

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)